Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that bimatoprost stimulated hair growth in both human scalp follicle cultures and mouse pelage in vivo, suggesting it might offer a promising treatment for scalp alopecias.

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This article reviews the pharmacology of bimatoprost and prostamide F2α, highlighting bimatoprost's therapeutic applications in glaucoma, hair growth, and potential fat reduction, without reporting new experimental results.

This review discusses the potential applications of prostaglandin F2α analogs for certain types of alopecia and hypopigmentation, but reports no new experimental results.

This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This article reviews the cellular dynamics affecting dermal papilla size in androgenetic alopecia and suggests targeting DP size could improve therapies, but it presents no new clinical data.

This article reports a case where the IOP-lowering drug bimatoprost was associated with eyelash hypertrichosis.

In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.

This study found that isolated human scalp hair follicles express PGE2 genes and EP2 protein, suggesting PGE2 may play a crucial role in regulating hair growth.

Bimatoprost gel makes eyelashes grow longer, but may cause side effects and should be monitored by an eye doctor.

This article reviews various treatments for alopecia, highlighting that minoxidil, finasteride, PRP therapy, and hair transplants are the most commonly used options, but it reports no new clinical results.

The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

The conference highlighted new diagnostic tools, the role of genetics in hair loss, and emerging treatments.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This review discusses advancements in cell culture techniques for hair growth treatments and provides insights into the potential and challenges of follicular cell implantation, reporting no new clinical results.

This study found that kukui nut oil (AMS oil) promotes hair growth in human hair follicle cultures by increasing PGF2α levels and activating Nrf2 signaling, and a human trial confirmed its efficacy in enhancing eyelash growth.

This review discusses the pathogenesis, clinical properties, and management of alopecia areata, highlighting the need for future treatment strategies, and reports no new clinical results.

In this narrative review, researchers evaluated existing literature on the treatment of frontal fibrosing alopecia, finding that while no curative treatment exists, clinical improvements can be achieved through personalized and combined therapy approaches.

New drug shows promise for better hair growth in baldness treatment.

This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.

This review discusses various therapeutic options for frontal fibrosing alopecia and highlights the need for more research, as existing data are largely retrospective and lack precise treatment guidelines.

This review explores the therapeutic applications of bimatoprost, including its role in glaucoma treatment, hair growth stimulation, and potential effects on fat deposition, but reports no new experimental findings.

In this study, applying FGF-2-containing dalteparin/protamine nanoparticles to the scalp was associated with a significant increase in hair diameter over six months among participants with thin hair.

This review discusses the concept of drug repositioning and highlights fragmin and protamine as emerging biomaterials for tissue engineering and regenerative medicine, but it reports no new clinical results.

LMWP-PDGFA shows promise for improving hair health and treating hair loss with fewer side effects.

This review discusses the safety and efficacy of bimatoprost ophthalmic solution 0.03% for enhancing eyelash growth by influencing the eyelash hair cycle and follicles, and it reports no new results.

In this case report, a 60-year-old woman with eyebrow hypotrichosis experienced significant and lasting eyebrow growth after daily use of bimatoprost 0.03% solution, highlighting its potential as an effective treatment for eyebrow hair restoration.

This study found that PRP combined with dalteparin and protamine microparticles may enhance hair growth by increasing hair thickness compared to PRP alone.